Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2(†)

BACKGROUND: The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival (PFS) by more than twofold in patients with hormone-receptor-positive (HR(+)), HER2-negative advanced breast cancer that recurred or progressed dur...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Ann Oncol
Päätekijät: Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., Burris, H. A., Provencher, L., Neven, P., Gnant, M., Shtivelband, M., Wu, C., Fan, J., Feng, W., Taran, T., Baselga, J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2014
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6267855/
https://ncbi.nlm.nih.gov/pubmed/25231953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdu456
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia